Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) - Total Liabilities

Latest as of March 2026: CN¥367.80 Million CNY ≈ $53.82 Million USD

Based on the latest financial reports, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has total liabilities worth CN¥367.80 Million CNY (≈ $53.82 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 600671 net asset momentum to track the company's year-over-year net asset growth rate.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Total Liabilities Trend (1993–2025)

This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Hangzhou TianMuShan Pharmaceutical Enter (600671) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Competitors by Total Liabilities

The table below lists competitors of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Tivan Ltd
AU:TVN
Australia AU$13.44 Million
Magnetic Resources NL
AU:MAU
Australia AU$1.59 Million
Berto Acquisition Corp. Ordinary Shares
NASDAQ:TACO
USA $11.94 Million
Hangzhou Landscape Architecture Design Institute Co Ltd
SHE:300649
China CN¥402.17 Million
LF Corp
KO:093050
Korea ₩1.27 Trillion
Sesoda Corp
TW:1708
Taiwan NT$5.35 Billion
IS Dongseo
KO:010780
Korea ₩1.99 Trillion
Yung Chi Paint & Varnish Mfg Co Ltd
TW:1726
Taiwan NT$1.68 Billion

Liability Composition Analysis (1993–2025)

This chart breaks down Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hangzhou TianMuShan Pharmaceutical Enter (600671) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.84 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 4.98 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.79 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2025)

The table below shows the annual total liabilities of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥348.04 Million
≈ $50.93 Million
-2.36%
2024-12-31 CN¥356.44 Million
≈ $52.16 Million
+22.77%
2023-12-31 CN¥290.34 Million
≈ $42.49 Million
-1.70%
2022-12-31 CN¥295.36 Million
≈ $43.22 Million
-12.64%
2021-12-31 CN¥338.09 Million
≈ $49.47 Million
-3.18%
2020-12-31 CN¥349.18 Million
≈ $51.10 Million
-11.29%
2019-12-31 CN¥393.60 Million
≈ $57.60 Million
-1.35%
2018-12-31 CN¥398.99 Million
≈ $58.39 Million
+12.65%
2017-12-31 CN¥354.18 Million
≈ $51.83 Million
+47.57%
2016-12-31 CN¥240.01 Million
≈ $35.12 Million
+10.29%
2015-12-31 CN¥217.63 Million
≈ $31.85 Million
+8.60%
2014-12-31 CN¥200.40 Million
≈ $29.32 Million
-12.87%
2013-12-31 CN¥230.01 Million
≈ $33.66 Million
+13.21%
2012-12-31 CN¥203.17 Million
≈ $29.73 Million
+16.09%
2011-12-31 CN¥175.00 Million
≈ $25.61 Million
+5.64%
2010-12-31 CN¥165.66 Million
≈ $24.24 Million
+17.88%
2009-12-31 CN¥140.53 Million
≈ $20.56 Million
+9.12%
2008-12-31 CN¥128.78 Million
≈ $18.85 Million
-1.81%
2007-12-31 CN¥131.16 Million
≈ $19.19 Million
+13.03%
2006-12-31 CN¥116.04 Million
≈ $16.98 Million
-12.97%
2005-12-31 CN¥133.32 Million
≈ $19.51 Million
+26.38%
2004-12-31 CN¥105.49 Million
≈ $15.44 Million
+1.56%
2003-12-31 CN¥103.88 Million
≈ $15.20 Million
-13.67%
2002-12-31 CN¥120.32 Million
≈ $17.61 Million
-23.42%
2001-12-31 CN¥157.11 Million
≈ $22.99 Million
+1.63%
2000-12-31 CN¥154.60 Million
≈ $22.62 Million
+61.58%
1999-12-31 CN¥95.68 Million
≈ $14.00 Million
+9.59%
1998-12-31 CN¥87.30 Million
≈ $12.78 Million
+23.94%
1997-12-31 CN¥70.44 Million
≈ $10.31 Million
+21.83%
1996-12-31 CN¥57.82 Million
≈ $8.46 Million
-35.04%
1995-12-31 CN¥89.00 Million
≈ $13.02 Million
-53.67%
1994-12-31 CN¥192.12 Million
≈ $28.11 Million
+610.98%
1993-12-31 CN¥27.02 Million
≈ $3.95 Million
--

About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

SHG:600671 China Drug Manufacturers - General
Market Cap
$393.11 Million
CN¥2.69 Billion CNY
Market Cap Rank
#13494 Global
#3993 in China
Share Price
CN¥22.06
Change (1 day)
-0.50%
52-Week Range
CN¥14.60 - CN¥22.50
All Time High
CN¥37.82
About

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared sl… Read more